INTRANASAL ADMINISTRATION

• US 20110053827A1
• Filed: 06/08/2007
• Published: 03/03/2011
• Est. Priority Date: 06/08/2006
• Status: Abandoned Application

• Current Assignee: OptiNose AS (OptiNose, Inc.)
• Original Assignee: OptiNose AS (OptiNose, Inc.)
• Inventors: Hafner, Roderick Peter
• Application Number:
  US12/303,667
• Publication Number:
  US 20110053827A1
• Time in Patent Office: Days
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/1796 for hormones for neuromediators A61K38/1787
• CPC Class Codes: A61K 38/2228 Corticotropin releasing factor [CRF] (Urotensin)
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61M 15/0091 mechanically breath-triggered
• CPC Class Codes: A61M 15/0098 Activated by exhalation
• CPC Class Codes: A61M 15/08 Inhaling devices inserted into the nose
• CPC Class Codes: A61M 2202/064 Powder
• CPC Class Codes: A61M 2210/0618 Nose
• CPC Class Codes: A61M 2210/0625 Mouth
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins to the upper posterior region of a nasal cavity of a subject, and in particular the olfactory bulb region.

Claims

1. A delivery device for delivering a protein formulation to the upper posterior region of a nasal cavity of a subject for uptake into the CNS of the subject, the delivery device comprising a nosepiece unit including a nosepiece for fitting to a nostril of a subject and a nozzle through which the formulation is in use delivered to the respective nasal cavity, and a delivery unit for delivering formulation through the nozzle of the nosepiece, wherein the delivery of the formulation is such as to provide for uptake of the protein to the CNS without triggering a significant immune response.

2-55. -55. (canceled)

56. A method of delivering a protein formulation to the upper posterior region of a nasal cavity of a subject for uptake into the CNS of the subject, the method comprising the step of delivering the formulation through a nozzle of a nosepiece of a delivery device into the nasal cavity of the subject, such as to provide for uptake of the protein to the CNS without triggering a significant immune response.

57-110. -110. (canceled)

111. A protein formulation for delivery to a nasal cavity of a subject for uptake into the CNS of the subject, the formulation being such as to provide for uptake of the protein to the CNS without triggering a significant immune response.

112-158. -158. (canceled)

159. A delivery device for delivering a substance to the nasal airway of a subject, the delivery device including a nosepiece having a replaceable outer sleeve.

160. The delivery device of claim 159, wherein the sleeve includes an indicator material which provides an indication of exposure to one or more of moisture and biomaterials, such as endotoxins.

161. A delivery device for delivering a substance to the nasal airway of a subject, the delivery device including a nosepiece having a plurality of removable sleeves which are removable successively to allow for exposure of a fresh sleeve.

162. The delivery device of claim 161, wherein the sleeves are individually peelable films.

163. The delivery device of claim 161, wherein one or more of the innermost sleeves are marked to indicate that a predeterminable number of the sleeves remain.

164. The delivery device of claim 161, wherein the sleeves include an indicator material which provides an indication of exposure to one or more of moisture and biomaterials, such as endotoxins.